



Cardiovascular Benefits after Weight Loss Surgery

John G. Zografakis, M.D., F.A.C.S.

Professor of Surgery
Northeast Ohio Medical University (NEOMED)
Assistant Professor of Surgery
Ohio University Heritage College of Osteopathic Medicine

Director, Advanced Laparoscopic Surgical Services
Co-Director, Weight Management Institute
Co-Director, Fellowship in Advanced Minimally Invasive and Bariatric Surgery
Summa Health, Akron, Ohio

Disclosure

- None

Objectives

- Epidemiology of obesity
- Indications for Metabolic and Bariatric Surgery (MBS)
 - Updated 2022
- Review Currently Endorsed MBS Procedures
- Cardiovascular Benefits after Surgical Weight Loss





Epidemiology of Obesity

Obesity by the Numbers


	USA	Ohio
Total Population	331 million	11.6 million
Adults	217 million	8.7 million
Percentage of adults	31%	33.5%
Adults (BMI > 30 kg/m ²)	67 million	2.8 million
Adults (BMI > 40 kg/m ²)	10.2 million	410,000
Adults (BMI > 50 kg/m ²)	1 million	40,000

Obesity Trends Among U.S. Adults

(*BMI ≥ 30 , or about 30 lbs overweight for 5'4" person)




Prevalence of Self-Reported Obesity Among U.S. Adults by State and Territory, BRFSS, 2021




*Sample size <50, the relative standard error (dividing the standard error by the prevalence) $\geq 30\%$, or no data in a specific year.



Medical Co-Morbidities



Medical Co-Morbidities Resolved





Indications for Metabolic and Bariatric Surgery (MBS)

Body Mass Index (BMI)

$$\text{BMI} = \frac{\text{weight (kg)}}{\text{height (m)} \times \text{height (m)}}$$

WHO Classification

- Ideal weight
- Overweight
- Moderate obesity (class I)
- Severe obesity (class II)
- Morbid obesity (class III)
- Super obese

BMI

20–24.9
25–29.9
30–34.9
35–39.9
40–49.9
50 +

Body Mass Index (BMI)

$$\text{BMI} = \frac{\text{weight (kg)}}{\text{height (m)} \times \text{height (m)}}$$

WHO Classification

BMI

• Ideal weight	20–24.9
• Overweight	25–29.9
• Moderate obesity (class I)	30–34.9
• -----	
• Severe obesity (class II)	35–39.9
• Morbid obesity (class III)	40–49.9
• Super obese	50 +

NIH Consensus Conference 1991

- Surgery is the only way to obtain ***consistent, permanent*** weight loss for obese patients
- Surgery indicated in patients with:
 - BMI of 40 kg/m² or over
 - BMI of 35-40 kg/m² with significant medical co-morbidity
 - Diabetes
 - HTN
 - OSA
 - Documented dietary attempts ineffective

2022 ASMBS/IFSO Updated Guidelines

[Obes Surg.](#) 2023; 33(1): 3–14.

PMCID: PMC9834364

Published online 2022 Nov 7. doi: [10.1007/s11695-022-06332-1](https://doi.org/10.1007/s11695-022-06332-1)

PMID: [36336720](https://pubmed.ncbi.nlm.nih.gov/36336720/)

2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery

[Dan Eisenberg](#),¹ [Scott A. Shikora](#),² [Edo Aarts](#),³ [Ali Aminian](#),⁴ [Luigi Angrisani](#),⁵ [Ricardo V. Cohen](#),⁶ [Maurizio de Luca](#),⁷ [Silvia L. Faria](#),⁸ [Kasey P.S. Goodpaster](#),⁴ [Ashraf Haddad](#),⁹ [Jacques M. Himpens](#),¹⁰ [Lilian Kow](#),¹¹ [Marina Kurian](#),¹² [Ken Loi](#),¹³ [Kamal Mahawar](#),¹⁴ [Abdelrahman Nimeri](#),¹⁵ [Mary O’Kane](#),¹⁶ [Pavlos K. Papasavas](#),¹⁷ [Jaime Ponce](#),¹⁸ [Janey S. A. Pratt](#),^{1,19} [Ann M. Rogers](#),²⁰ [Kimberley E. Steele](#),²¹ [Michel Suter](#),^{22,23} and [Shanu N. Kothari](#)²⁴

2022 ASMBS/IFSO Updated Guidelines


Metabolic and Bariatric surgery (MBS) recommended for

- Individuals with BMI >35 kg/m²
 - Regardless of presence, absence or severity of co-morbidities
- BMI 30-34.9 kg/m² with metabolic disease (T2DM)
- BMI adjusted for Asian population suggests that BMI > 25 kg/m² suggests clinical obesity
 - BMI > 27.5 kg/m² should be offered MBS




Surgical Procedures

Restrictive Stapling Procedures




Adjustable
Gastric Band




Vertical Sleeve
Gastrectomy

Anastomotic Stapling Procedures




Roux-en-Y
Gastric Bypass

Anastomotic Stapling Procedures




Roux-en-Y
Gastric Bypass




Vertical Sleeve
Gastrectomy (LSG)

LRYGB and LSG make up over 90% of all MBS performed

Anastomotic Stapling Procedures




One Anastomosis
Gastric Bypass




Single Anastomosis
Duodeno-ileostomy
SADI-S

Weight Loss after Surgery



Why Do We Care?



**Morbid Obesity decreases
life span 5-15 years**



Cardiovascular Benefits

Started with HTN

- Obesity is major cause for HTN
 - Three out of four patients with HTN have obesity
- Increases risk of other diseases
 - CHF, stroke, atrial fibrillation and renal disease

1. Landsberg, Lewis, et al. "Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension." *Obesity* 21.1 (2013): 8-24.

Swedish Obesity Study

The NEW ENGLAND
JOURNAL *of* MEDICINE

ESTABLISHED IN 1812


DECEMBER 23, 2004

VOL. 351 NO. 26

Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery

Lars Sjöström, M.D., Ph.D., Anna-Karin Lindroos, Ph.D., Markku Peltonen, Ph.D., Jarl Torgerson, M.D., Ph.D.,
Claude Bouchard, Ph.D., Björn Carlsson, M.D., Ph.D., Sven Dahlgren, M.D., Ph.D., Bo Larsson, M.D., Ph.D.,
Kristina Narbro, Ph.D., Carl David Sjöström, M.D., Ph.D., Marianne Sullivan, Ph.D., and Hans Wedel, Ph.D.,
for the Swedish Obese Subjects Study Scientific Group*

Swedish Obesity Study



Improvement in HF



Contents lists available at [ScienceDirect](#)

International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard

Bariatric Surgery and Incident Heart Failure: a Propensity Score Matched Nationwide Cohort Study

Luke Kostanjsek^{a,1,2}, Maddalena Ardissino^{a,1,2}, Osama Moussa^{b,2}, Bilal Rayes^{c,2},
Ravi Amin^{a,2}, Peter Collins^{a,d,*,2}, Sanjay Purkayastha^{a,b,e,2}

Improvement in HF

- Patients that underwent MBS had significantly lower incidence of new HF in patients
 - 95% CI, $p = 0.0011$

Reduction of MACE

How Much Weight Loss is Required for Cardiovascular Benefits? Insights From a Metabolic Surgery Matched-cohort Study

Aminian, Ali MD^{*}; Zajichek, Alexander MS[†]; Tu, Chao MS[†]; Wolski, Kathy E. MPH[‡]; Brethauer, Stacy A. MD[§]; Schauer, Philip R. MD[¶]; Kattan, Michael W. PhD[†]; Nissen, Steven E. MD[‡]

[Author Information](#) 

Annals of Surgery 272(4):p 639-645, October 2020. | DOI: 10.1097/SLA.0000000000004369

Reduction of MACE

Results:

A total of 7201 patients (1223 surgical and 5978 nonsurgical) with a median follow-up time of 4.9 years (interquartile range, 3.5–7) were included. The positive effect of metabolic surgery was still present after adjusting for weight loss amounts, suggesting that there are weight loss-independent factors contributing to a reduction in risk of MACE and all-cause mortality in the surgical cohort. After considering the weighted estimates from a diverse set of models, the risk of MACE decreases after approximately 10% of weight is lost in the surgical group and approximately 20% in the nonsurgical group. For all-cause mortality, the threshold for benefit appeared to be approximately 5% weight loss after metabolic surgery and 20% in the nonsurgical group.

Conclusions:

This large matched-cohort study identified the minimum weight loss thresholds for reduction in risk of MACE and all-cause mortality in patients with obesity and diabetes. Furthermore, in our analysis, the effect of surgery was still present after accounting for weight loss, which may suggest the presence of weight-independent beneficial effects of metabolic surgery on MACE and survival.

CV Improvement After MBS



Journal of the American College of
Cardiology

Volume 79, Issue 15, 19 April 2022, Pages 1429-1437




Original Investigation

Long-Term Cardiovascular Outcomes After Bariatric Surgery in the Medicare Population

Amgad Mentias MD, MS^a  , Ali Aminian MD^b, Dalia Youssef MD^c,
Ambarish Pandey MD^d, Venu Menon MD^a, Leslie Cho MD^a,
Steven E. Nissen MD^a, Milind Y. Desai MD, MBA^a

CV Improvement After MBS



Reduction of HF Mortality

[J Am Heart Assoc.](#) 2021 Apr 6; 10(7): e019323.

PMCID: PMC8174344


Published online 2021 Mar 23. doi: [10.1161/JAHA.120.019323](https://doi.org/10.1161/JAHA.120.019323)

PMID: [33754795](https://pubmed.ncbi.nlm.nih.gov/33754795/)

Potential Effects of Bariatric Surgery on the Incidence of Heart Failure and Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Obesity and on Mortality in Patients With Preexisting Heart Failure: A Nationwide, Matched, Observational Cohort Study

[Gudrún Höskuldsdóttir](#), MD,^{1,2} [Naveed Sattar](#), PhD,³ [Mervete Miftaraj](#), MSc,⁴ [Ingmar Näslund](#), PhD,⁶ [Johan Ottosson](#), PhD,⁶ [Stefan Franzén](#), PhD,^{4,5} [Ann-Marie Svensson](#), PhD,^{1,4} and [Björn Eliasson](#), PhD^{1,2}

Reduction of HF Mortality



Reduction of HF Mortality

- Bariatric Surgery associated with lower risk of HF and AF in patients with T2DM and obesity
- Surgical treatment of obesity may be safe and reduce mortality in patients with T2DM and preexisting HF



Cardiovascular Benefits after Weight Loss Surgery

John G. Zografakis, M.D., F.A.C.S.

Professor of Surgery
Northeast Ohio Medical University (NEOMED)
Assistant Professor of Surgery
Ohio University Heritage College of Osteopathic Medicine

Director, Advanced Laparoscopic Surgical Services
Co-Director, Weight Management Institute
Co-Director, Fellowship in Advanced Minimally Invasive and Bariatric Surgery
Summa Health, Akron, Ohio